The civic record
Read. Follow. Verify.Maintaining Investments in New Innovation Act (H.R. 5547)
Record date · December 17, 2024
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
This bill extends the period of time that certain advanced, genetically targeted drugs are protected from government price negotiations under the Social Security Act. It increases the exclusivity period for these specific products from 7 years to 11 years.
The bill changes the timeline for when the federal government can begin negotiating prices for advanced genetic therapies, potentially delaying price regulation for these drugs by four years to encourage continued investment in genetic technology.
- The Social Security Act includes provisions that allow the federal government to negotiate prices for certain high-cost drugs that have been on the market for a specific number of years. context
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Pharmaceutical companies developing genetic therapies
These companies would have a longer period of market exclusivity before their products are subject to federal price negotiations.
Medicare program
The program's ability to negotiate prices for specific advanced drugs is delayed by four years under this proposal.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What is an 'advanced drug product' under this bill?
How does this bill change current drug pricing rules?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently filed. The next step in the legislative lifecycle is Committee.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
IONIS PHARMACEUTICALS, INC.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Extension of Exclusivity
The bill specifically targets 'advanced drug products' for a longer period of protection from price negotiation than standard drugs.
Connected Entities
Sources
www.congress.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy50Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools